Digital health has spent years competing on convenience: a smaller device, a cleaner app, a faster path to data at home.
While these improvements are important, digital health providers have not addressed whether a solution reaches beyond early adopters, to the people who need it and whether they can afford the technology over time.
Leading an AI-powered cardiology company, I have learned that the payment model needs to shape the product itself. It influences which patients can participate and what clinical support is required. It affects how data reaches care teams and whether a promising technology can become part of routine care rather than another out-of-pocket expense.
For digital health leaders, reimbursement belongs much earlier in the product-development conversation.
PAYMENT SHAPES ACCESS
Traditional fee-for-service reimbursement was built around discrete events such as an office visit or procedure. Many digital health products instead create value between visits through remote monitoring, timely outreach, and continuous patient engagement.
That difference has created friction. A product may generate clinically useful information every day, while the payment system recognizes only a narrow set of billable interactions. When that happens, developers can be tempted to optimize for consumer adoption alone, even when the people facing the greatest barriers to care are the least able to pay out of pocket.
CMS’s ACCESS Model signals a meaningful shift in the conversation. The voluntary model brings technology-supported chronic care into an outcomes-based framework that emphasizes affordability and integration with existing care teams, along with quality standards and outcome reporting. More than 160 healthcare organizations, including ours, are participating across areas including cardiovascular-kidney-metabolic care, musculoskeletal care, and behavioral health.
The lesson is that payment design is beginning to catch up with how chronic care is delivered, which is continuous and across settings, and in partnership with clinicians.
CHRONIC CARE IS CONNECTED
This shift in delivery is important because chronic disease rarely arrives one diagnosis at a time.
Healthcare organizations have historically divided care by specialty: cardiology for the heart, nephrology for the kidneys, and endocrinology for metabolic health. Patients experience a different reality. Their conditions and medications, as well as risk factors and day-to-day decisions, overlap.
The 2026 AHA/ACC/ADA/ASN guideline on cardiovascular-kidney-metabolic syndrome reflects this reality. It describes the condition as an interconnected relationship among metabolic risk factors, chronic kidney disease, and cardiovascular disease—and calls for a more unified approach across clinicians and specialties.
The population need is substantial. The Centers for Disease Control and Prevention reports that three in four U.S. adults have at least one chronic condition, while more than half have two or more.
For leaders building digital health products, that should change the design brief. The goal should be to make data useful within a care model that recognizes how conditions intersect. The goal should also ensure that the people generating that data can receive support when it matters.
3 PRODUCT QUESTIONS
Here are three questions I believe executives should bring into product planning earlier.
1. Does the payment model match the care model?
Reimbursement affects product requirements: the patient population, clinical workflow, documentation burden, care-team roles, and success measures.
A product designed only for direct consumer purchase will make different assumptions than one intended to fit into clinician-led chronic care. Neither approach is inherently wrong. But leaders need to make the choice consciously, because it determines who can use the product and under what conditions.
2. Does the data lead to a decision?
More monitoring does not automatically produce better care. Without a clear clinical workflow, continuous tracking creates alert fatigue for clinicians and confusion or anxiety for patients.
The most useful products collect signals but also provide validated insights. Clinical-grade ECG readings, for example, can help a care team determine what needs attention and what can wait. It supports what action is appropriate. The insights give patients a clearer role between appointments without asking them to become their own care coordinators.
That is a product challenge as much as a clinical one. It requires leaders to decide which data matter, who responds to it, and how the handoff works when a follow-up is required.
3. Are we measuring access, not just adoption?
Device shipments, downloads, and engagement metrics are useful, but incomplete. They can show whether a product is gaining traction without showing whether it is reaching people who face cost, geography, mobility, or care-access barriers.
Leadership should also consider whether the model they are using makes ongoing support available to patients who otherwise would not have it. That measure brings reimbursement into focus. Payment is a revenue mechanism, but it can also determine whether sustained care is available to every patient.
BUILD THE WHOLE SYSTEM
The next phase of digital health will be shaped by companies that can connect a useful product with a workable clinical model and a durable payment path.
That changes the executive conversation from what the company can build to who it’s designed to reach, how it will fit into care, and what outcome makes the investment worth sustaining.
This may feel less glamorous than a product launch. But this is where access is decided.
Priya Abani is CEO of AliveCor.